Pneumatic Shoe Lacing Apparatus
This invention provides a pneumatic shoe lacing apparatus for the pneumatic lacing of shoe.
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173680 | Cannabinoid receptor modulators Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein: X is a bond, or a divalent radical selected from —C(R10)(R11)—*, —C(R10)(R11)—O... | 05/08/2012 |
| 8163775 | Allosteric modulators of metabotropic glutamate receptors The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other di... | 04/24/2012 |
| 8148404 | Modulators of CB1 receptors Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh ga... | 04/03/2012 |
| 8143287 | Thrombopoietin mimetics The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment... | 03/27/2012 |
| 8133905 | Biphenyl compounds useful as muscarinic receptor antagonists The invention provides compounds of formula I: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, Y, R1, R2, and R3 are as defined in the specification. The compou... | 03/13/2012 |
| 8129412 | Hydantoin derivatives useful as metalloproteinase inhibitors Formula (I) wherein R1 is a (2-4C)alkyl and is substituted by two or more fluorine groups and R2 is methyl or ethyl, or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and... | 03/06/2012 |
| 8129413 | Crystalline forms of MC4R agonist and process for synthesis The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms ther... | 03/06/2012 |
| 8124627 | Biphenyl compounds useful as muscarinic receptor antagonists The invention provides compounds of formula I: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, R1, R2, and R3 are as defined in the specification. The compounds... | 02/28/2012 |
| 8119663 | Heteroaryl-substituted piperidines The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in parti... | 02/21/2012 |
| 8119664 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and v... | 02/21/2012 |
| 8093268 | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl-piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium chann... | 01/10/2012 |
| 8088797 | Substituted N-(4-cyano-1-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof The present invention relates to compounds corresponding to formula (I): Wherein X, R1, R2, R3 and R4 are as defined herein. The invention further relates to preparation and thera... | 01/03/2012 |
| 8088798 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders. ... | 01/03/2012 |
| 8084467 | Pyrazole derivatives as cannabinoid receptor antagonists One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the CB1 cannabinoid receptor. A further aspect of the i... | 12/27/2011 |
| 8084469 | Substituted piperidines The invention relates to compounds of the formula (I) to processes for the preparation thereof, and to the use thereof for the treatment of cardiovascular disorders and tumor disorders. ... | 12/27/2011 |
| 8084468 | Fungicidal amides Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, A, G, W1, Q, X, Z, and n are ... | 12/27/2011 |
| 8067439 | Biphenyl compounds useful as muscarinic receptor antagonists This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specificat... | 11/29/2011 |
| 8044071 | Method for reducing side effects of CBreceptor agonist therapy using a combination of a selective CBreceptor agonist and a selective CBreceptor antagonist The present application describes a method of treating pain with a combination of a CB2 cannabinoid receptor agonist and rimonabast. ... | 10/25/2011 |
| 8044072 | Pyrrole derivatives, preparation thereof and therapeutic use thereof The invention relates to compounds having the formula (I): Wherein R1, R2, R3, R4, R5, R6, R7 and R8 and A-R9 are as defined... | 10/25/2011 |
| 8039489 | Guanidine-containing compounds useful as muscarinic receptor antagonists The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are mus... | 10/18/2011 |
| 8030331 | Allosteric modulators of metabotropic glutamate receptors The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other di... | 10/04/2011 |
| 7989475 | Substituted pyrazoles, compositions containing such compounds and methods of use The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus. | 08/02/2011 |
| 7977358 | Pyrazol derivatives The invention is concerned with novel pyrazol derivatives of formula (I), wherein R1, R2, R3, R4, X and Y are as defined herein, as wel... | 07/12/2011 |
| 7956070 | Piperidines as chemokine modulators (CCR) Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma). ... | 06/07/2011 |
| 7939547 | Compounds and compositions as channel activating protease inhibitors The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, in... | 05/10/2011 |
| 7910606 | Pyrazole-derivatives as factor Xa inhibitors The present invention is directed to a compound of formula I, in which R0; R1; R2; R3; R4; Q; V, G and M have the meanings indicated below. The compound of formula I is... | 03/22/2011 |
| 7872026 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radical of formulae (a) to (c) below: | 01/18/2011 |
| 7872027 | Low molecular weight Myc-max inhibitors Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are prov... | 01/18/2011 |
| 7855218 | Compounds Compounds of formula (I) wherein the variables are defined herein, pharmaceutical compositions thereof and methods for treatment using the same. ... | 12/21/2010 |
| 7834035 | Allosteric modulators of metabotropic glutamate receptors The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other di... | 11/16/2010 |
| 7829581 | Prodrugs of pyrazoline compounds, their preparation and use as medicaments The present invention relates to prodrugs of pyrazoline compounds of formula I, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. ... | 11/09/2010 |
| 7825140 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3.... | 11/02/2010 |
| 7825139 | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV Compounds that selectively inhibit dipeptidyl peptidase-IV over closely related dipeptidyl peptidases are those of Formula (I): as well as pharmaceutically acceptable salts thereof, cyclic isomers thereof, prodrugs thereof,... | 11/02/2010 |
| 7816377 | Tubulysin analogues The invention relates to tubulysin derivatives of general formula (II), said derivatives having a cytostatic effect. ... | 10/19/2010 |
| 7795279 | Method of inhibiting FLT3 kinase A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: ... | 09/14/2010 |
| 7786143 | Thiazolyl piperidine derivatives The present invention relates to compounds of formula I wherein R1, R2 and R3 are as defined in the description and claims. It further relates to pharmaceutically acceptable salts thereof as... | 08/31/2010 |
| 7709503 | Pyrrol derivatives with antibacterial activity Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also des... | 05/04/2010 |
| 7700627 | Therapeutic substituted lactams Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, prodrug, or bioisostere thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed. ... | 04/20/2010 |
| 7700626 | Compositions containing opioid antagonists Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed... | 04/20/2010 |
| 7696230 | Drugs for chronic pains Nitro-oxyderivative compounds or salts thereof having the following general formula (I): A-(B)b0-(C)c0—NO2 wherein: c0 is an integer and is 0 or 1, b0 is an integer and is 0 or 1, A=R-T1-, wherein R is the radical of an ... | 04/13/2010 |